pocketful logo
Marksans Pharma Ltd logo

Marksans Pharma Ltd

NSE: MARKSANS BSE: 524404

₹203.28

(2.79%)

Tue, 19 May 2026, 03:51 am

Marksans Pharma Share Price Live Chart

1 Day

(2.79%)

No Result Found

Summary

  • Market Cap

    9863.11

  • Net Profit

    382.62

  • P/B

    4.08

  • Sector P/E

    35.36

  • P/E

    26.47

  • EV/EBITDA

    16.18

  • Debt/Equity (Industry)

    0.26

  • Interest Cover (Industry)

    10.95

  • ROCE (Industry)

    16.47

  • RONW (Industry)

    14.44

  • ROE

    16.89

  • ROCE

    20.19

  • Debt/Equity

    0.12

  • EPS (TTM)

    7.95

  • Dividend Yield

    0.37

  • Book Value

    59.32

  • Interest Cover

    44.22

Analysis

all

thumbs up icon

Pros

  • Marksans Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Marksans Pharma is profitable, therefore cash runway is not a concern.
  • Marksans Pharma is profitable, therefore cash runway is not a concern.
  • Debt is well covered by operating cash flow (880.5%, greater than 20% of total debt).
  • Debt is covered by short term assets, assets are 24.8x debt.
thumbs up icon

Cons

  • Marksans Pharma is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
  • No need to calculate the sustainability of Marksans Pharma's dividends as it is not paying a notable one for India.
  • Marksans Pharma is not paying a notable dividend for India, therefore no need to check if the payments are stable.
  • Marksans Pharma's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Marksans Pharma's dividend is below the markets top 25% of dividend payers in India (3.08%).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters43.8743.8743.8743.8743.87
FII16.768.1216.9219.8822.20
DII6.575.915.285.504.56
Public32.7942.0933.9330.7529.37
Government00000

Read More

Technical Analysis

RSI

72.84

MACD

9.41

50 DMA

180.25

200 DMA

181.95

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic250.46215.38200.01180.30164.93145.22110.14
Fibonacci215.38201.98193.70180.30166.90158.62145.22
Camarilla194.28191.06187.85180.30181.41178.20174.98

Pivots Level: Classic

R3

+70.16

250.46

R2

+35.08

215.38

R1

+19.70

200.01

180.30
180.30
Pivot Point
LTP: 220.30

S1

-15.38

164.93

S2

-35.08

145.22

S3

-70.16

110.14

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    205.45

  • 20-EMA

    197.45

  • 30-EMA

    192.31

  • 50-EMA

    186.73

  • 100-EMA

    183.58

  • 200-EMA

    189.44

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
05 Feb 2026board-meetingsQuarterly Results
13 Nov 2025board-meetingsQuarterly Results, Nine Months Results
11 Jul 2025agm
01 Jul 2025dividendFinal Dividend - Rs. - 0.801 Aug 2025
19 May 2025dividend₹0.80 Dividend /Share01 Aug 2025
19 Aug 2024agm
17 Aug 2024dividendFinal Dividend - Rs. - 0.617 Sept 2024
30 May 2024dividend₹0.60 Dividend /Share17 Sept 2024
02 Aug 2023agm
30 May 2023dividend₹0.50 Dividend /Share07 Jun 2023

Read More

Peer Comparison

Marksans Pharma Ltd logo

Marksans Pharma Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Read More

Marksans Pharma Ltd About

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. It operates two manufacturing facilities in Goa and maintains two R&D centers, one located in Goa and the other in Navi Mumbai.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1992

Headquarters

CEO

Mark Saldanha

Employees

Contact

Website icon

Website

http://www.marksanspharma.com

Email icon

Email

companysecretary@marksanspharma.com ; info@marksan

Phone icon

Phone

91-22-40012000

Location icon

Location

11th Flr GRANDEUR Oshiwara, Veera Desai Extn Rd Andheri(W), Mumbai, Maharashtra, 400053

Read More

Marksans Pharma Ltd Company History

YearHistory
2017
  • Marksans Pharma Goa plant received UK MHRA approval.
  • Marksans Pharma received certificate of GMP Compliance of a Manufacturer from Australian government, Department of Health, Therapeutic Goods Administration.
2021
  • Marksans Pharma received USFDA approval for Acetaminophen ER Tablets.
2022
  • The company completed the process of acquiring 100% share capital of Access Healthcare for Medical Products LLC based in Dubai, UAE.
  • Marksans Pharma received USFDA approval for Cetirizine Hydrochloride Tablets.
  • Marksans Pharma received UK MHRA approval for Bells Healthcare All in One Oral Solution.
2023
  • Marksans Pharma Limited's wholly owned subsidiary Relonchem Limited received Marketing Authorisation for Cyanocobalamin 50mg film coated tablets.
  • Marksans Pharma completed the acquisition from Tevapharm India, expanding the existing manufacturing capacity in India.
  • Marksans Pharma received UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution.
2024
  • Marksans Pharma Limited receives USFDA approval for Loratadine Tablets USP 10mg.
  • US FDA Inspection at Marksans Pharma's manufacturing facility located at Verna, Goa was successfully closed.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
UNIFI CAPITAL PRIVATE LIMITEDbulkBuy7241309231.528 Jul 2025
UNIFI CAPITAL PRIVATE LIMITED -BLENDED RANGOLIblockBuy3247600249.9511 Jun 2025
SOCIETE GENERALEblockBuy920184249.9511 Jun 2025
UNIFI CAPITAL PRIVATE LIMITEDblockBuy594000249.9511 Jun 2025
UNIFI BLEND FUND 2blockBuy3000000249.9511 Jun 2025
UNIFI BCAD FUNDblockBuy560000249.9511 Jun 2025
UTI MUTUAL FUNDblockBuy414093249.9511 Jun 2025
CITIGROUP GLOBAL MARKETS SINGAPORE PTE LIMITEDblockBuy400081249.9511 Jun 2025
BANDHAN MUTUAL FUNDblockBuy600000249.9511 Jun 2025
SUBHKAM VENTURES I PRIVATE LIMITEDblockBuy537485249.9511 Jun 2025

Read More

Marksans Pharma Ltd News

Marksans Pharma Board Meet on May 26 for Q4FY26 Results

Marksans Pharma schedules board meeting on May 26, 2026, to approve Q4FY26 audited financial results and consider dividend recommendation for FY2025-26.

12 May 2026

companies

Marksans Pharma Files SEBI Compliance Certificate

Marksans Pharma Limited submitted its quarterly certificate under SEBI Regulation 74(5) for Q4 FY26, confirming proper handling of dematerialized securities through its registrar Bigshare Services.

09 Apr 2026

companies

Marksans Pharma Gets USFDA Nod for Benzonatate Capsules

Marksans Pharma receives USFDA approval for Benzonatate Capsules USP in 100 mg and 200 mg strengths, expanding its US pharmaceutical portfolio with this cough suppressant medication.

01 Apr 2026

companies

Marksans Pharma Gets USFDA Nod for Benzonatate Capsules

Marksans Pharma receives USFDA approval for Benzonatate Capsules USP in 100 mg and 200 mg strengths, expanding its US pharmaceutical portfolio with this cough suppressant medication.

01 Apr 2026

companies

Marksans Pharma Opens Special Window for Share Transfer

Marksans Pharma announces SEBI-mandated special window for re-lodgment of physical share transfer requests from pre-April 2019 transactions, valid from February 5, 2026 to February 4, 2027.

11 Mar 2026

stocks

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800